TrialNature communications2024

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Paolo A Ascierto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.